Study on the antihypertensive efficacy and safety of sacubitril and valsartan sodium tablets in the morning and evening

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054606

Enrollment

Unknown

Registered

2021-12-21

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group1:Morning sacubitril and valsartan sodium tablets

Experimental group2:Sacubitril and Valsartan Sodium Tablets before going to bed

Experimental group3:Sacubitril valsartan sodium tablet twice daily group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Essential hypertension, aged>= 18 years, male or female; 2. Agree to participate in the trial and be able to adhere to the follow-up.

Exclusion criteria

Exclusion criteria: 1. Severe hypertension, malignant hypertension, hypertensive pressure emergency, hypertensive crisis, etc.; 2. Those with a history of acute stroke or dementia and hemodialysis; 3. History of angioedema, drug-related or other causes; 4. Liver function (ALT, AST, TBL) results >= twice the upper limit of normal, CKD stage 4 and above (eGFR5.5 mmol/L or <3.5 mmol/L; 6. Those who have a history of hypersensitivity to antihypertensive drugs (ARB, ACEI and renin inhibitor); 7. Patients with a clear history of intolerance to the study drug.

Design outcomes

Primary

Measure	Time frame
Blood pressure;	—

Secondary

Measure	Time frame
Dizziness;	—

Countries

China

Contacts

Public ContactHuang Yuqing

Guangdong Provincial People's Hospital

hyq513@126.com+86 13172054256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026